Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules.
about
Sunitinib: the antiangiogenic effects and beyondSunitinib in the treatment of metastatic renal cell carcinomaAssessment of efficacy, safety and quality of life of 110 patients treated with sunitinib as first-line therapy for metastatic renal cell carcinoma: experience in real-world clinical practice in Japan.Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma.Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis.Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal TumorFirst-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience.Prognostic Value of Serum Lactate Dehydrogenase in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian "Real-World" SAX Study.Prognostic role of pretreatment serum albumin in renal cell carcinoma: a systematic review and meta-analysis.Recent aspects of sunitinib therapy in patients with metastatic clear-cell renal cell carcinoma: a systematic review of the literature.Alternate sunitinib schedules in patients with metastatic renal cell carcinoma.Kidney cancer and 2014: is innovation really over?Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies.Emerging therapeutic approaches in renal cell carcinoma.Dosing strategies and optimization of targeted therapy in advanced renal cell carcinoma.Real-life patterns of use, safety and effectiveness of sunitinib in first-line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study.Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies.Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma.Feasibility, efficacy and safety of tyrosine kinase inhibitor treatment in hemodialyzed patients with renal cell cancer: 10 years of experience.Sunitinib in kidney cancer: 10 years of experience and development.How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma.Real-world experience of the feasibility and tolerability of the 2/1 dosing schedule with sunitinib in the treatment of patients with advanced renal cell carcinoma in Australia.Immunogenic Chemotherapy Sensitizes Renal Cancer to Immune Checkpoint Blockade Therapy in Preclinical Models.Detecting functional changes with [(18)F]FAZA in a renal cell carcinoma mouse model following sunitinib therapy.Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study.Development and plasticity of meningeal lymphatic vessels.Improved health-related quality of life of patients with metastatic renal cell carcinoma treated with a 2 weeks on and 1 week off schedule of sunitinib.The use of sunitinib in renal cell carcinoma: where are we now?Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence.RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial.[Side effect management of tyrosine kinase inhibitors in urology : Gastrointestinal side effects].Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection.Optimal dynamic regimens with artificial intelligence: The case of temozolomide.Improved Long-Term Clinical Outcomes And Safety Profile Of Sunitinib Dosing Schedule With 4/2 Switched To 2/1 In Patients With Metastatic Renal Cell CarcinomaSunitinib rechallenge with dose escalation in progressive metastatic renal cell carcinoma: A case report and literature review
P2860
Q28066499-37A9F8EF-7DF1-42D1-A66F-E6028BA446B2Q28072057-9E20CD1D-0017-43D8-8EF2-84C77006A924Q33415035-8128ACA6-4AE7-4BF8-B5B8-A5B5C1392B98Q33417828-775DDD78-ECB1-4916-A77E-874FAA3360F3Q33424769-68279B2C-79B0-4370-A801-BF8C5D882DF0Q33432047-0C0FAD14-27C0-49C6-8FB1-7790D63B31DDQ33696649-6D8DF31B-82FA-4B84-AFB8-FFADA462B929Q36197277-EAF3BF4C-286D-497D-97F9-66E9723F12BDQ37290050-EACC2A5F-B726-4455-B177-E0A65F5A0C5BQ37391865-67091B09-9010-4E21-9B7E-2C0D74CAB4D0Q38334611-7B5D58B3-9703-466F-A9F5-F8BEB7D83CCEQ38335105-9F78B728-42D0-4B3B-810B-3296651327A8Q38465870-1B2C3336-DB67-4966-8168-9ACDDE061266Q38487988-44FBBFEA-C7BE-4020-A5D0-118DF2BC04ECQ38587958-5B35F531-9A07-44A0-A8D2-24AD04B03940Q38655156-33CB41D2-62AC-4A1D-B51C-1652AAC16D6EQ38749318-BAF007B9-EDFD-415B-A637-ACFB252CFE34Q38768663-24987F2C-71D3-4424-AB9C-49AB529DAFA9Q38799848-6A25C43A-F759-4879-9C9A-A15BEF0CF66EQ38975599-B883D201-05D5-42FA-921D-6F3B02C9309BQ39038214-9093B41F-8BA5-4398-BB0E-4E4FC5DA516BQ39065451-C9525F91-6D2A-4096-8249-769AEBBE89B4Q39254111-0776179A-AC88-40B0-9999-B2C1F1E57B06Q41056243-8930B3CC-4AB4-4066-81F2-8378F3C8ED4EQ41505826-196F9197-B590-4974-ABCB-172309C46781Q47151381-4FD660B1-0EA1-4137-B9AD-A1799FC3EDC4Q47344702-D25E21D2-587C-4BFF-B591-839ECB3CF46FQ48048760-389BDB67-5EE2-466F-896E-0B89B419E871Q48634468-810F827F-DF33-4DB2-BF1E-FEDCFBA9BBBBQ52319542-BB8FAA75-915D-4E04-8FCF-B3A2C1F7E9AFQ53197402-F5DA8199-2E1B-49B9-8B9A-E0664EF5CDE8Q54196218-D3D6CF82-A085-41E5-A2C2-55224E42EDCEQ55418935-4A880FFC-6099-4957-B15B-3415411A1504Q55450692-109575B7-D4C6-4944-AE8A-6864AABFC4C8Q57116754-1B566722-157F-4469-B342-16FFC5D4F06FQ58802067-288E6088-462B-41EE-AEFD-775AD4ACA4B9
P2860
Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules.
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Clinical outcomes for patients ...... ternative sunitinib schedules.
@ast
Clinical outcomes for patients ...... ternative sunitinib schedules.
@en
Clinical outcomes for patients ...... ternative sunitinib schedules.
@nl
type
label
Clinical outcomes for patients ...... ternative sunitinib schedules.
@ast
Clinical outcomes for patients ...... ternative sunitinib schedules.
@en
Clinical outcomes for patients ...... ternative sunitinib schedules.
@nl
prefLabel
Clinical outcomes for patients ...... ternative sunitinib schedules.
@ast
Clinical outcomes for patients ...... ternative sunitinib schedules.
@en
Clinical outcomes for patients ...... ternative sunitinib schedules.
@nl
P2093
P2860
P1476
Clinical outcomes for patients ...... ternative sunitinib schedules.
@en
P2093
Bradley J Atkinson
Eric Jonasch
Nizar M Tannir
Sarathi Kalra
Tharakeswara Bathala
Xuemei Wang
P2860
P304
P356
10.1016/J.JURO.2013.08.090
P407
P577
2013-09-07T00:00:00Z